<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-CPI-2538</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2538</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Цитокиновый профиль при внебольничной пневмонии у детей</article-title><trans-title-group xml:lang="en"><trans-title>Cytokine profile in community-acquired pneumonia in children</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0049-2194</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Изюрова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Iziurova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Изюрова Наталья Владимировна, ассистент кафедры пропедевтики детских болезней и педиатрии</p><p>454092, г. Челябинск, ул. Воровского, 64Тел.: 8 (963) 081-46-78</p></bio><bio xml:lang="en"><p>Iziurova Natalia V. Assistant Professor, Department of Propaedeutics of Children’s Diseases and Pediatrics</p><p>454092, Chelyabinsk, Vorovsky str., 64Phone: 7 (963) 081-46-78</p></bio><email xlink:type="simple">natusaz@live.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0536-0924</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савочкина</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Savochkina</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор кафедры клинической лабораторной диагностики</p><p>г. Челябинск</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Department of Clinical Laboratory Diagnostics</p><p>Chelyabinsk</p></bio><email xlink:type="simple">alina7423@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2367-875X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Узунова</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Uzunova</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, заведующая кафедрой пропедевтики детских болезней и педиатрии</p><p>г. Челябинск</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head, Department of Propaedeutics of Children’s Diseases and Pediatrics</p><p>Chelyabinsk</p></bio><email xlink:type="simple">propeddet@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4920-2338</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нохрин</surname><given-names>Д. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Nokhrin</surname><given-names>D. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.б.н., доцент кафедры микробиологии, иммунологии и общей биологии биологического факультета</p><p>г. Челябинск</p></bio><bio xml:lang="en"><p>PhD (Biology), Associate Professor, Department of Microbiology, Immunology and General Biology, Faculty of Biology</p><p>Chelyabinsk</p></bio><email xlink:type="simple">nokhrin8@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural Medical State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Челябинский государственный университет» Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Chelyabinsk State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>31</day><month>10</month><year>2022</year></pub-date><volume>24</volume><issue>5</issue><fpage>943</fpage><lpage>954</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Изюрова Н.В., Савочкина А.Ю., Узунова А.Н., Нохрин Д.Ю., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Изюрова Н.В., Савочкина А.Ю., Узунова А.Н., Нохрин Д.Ю.</copyright-holder><copyright-holder xml:lang="en">Iziurova N.V., Savochkina A.Y., Uzunova A.N., Nokhrin D.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2538">https://www.mimmun.ru/mimmun/article/view/2538</self-uri><abstract><p>Внебольничная пневмония относятся к числу наиболее распространенных острых инфекционных заболеваний. Заболеваемость внебольничной пневмонией среди детского населения значительно снизилась во всем мире, главным образом, из-за все более широкого использования эффективных средств профилактики. Тем не менее внебольничная пневмония остается распространенной причиной детской заболеваемости и смертности. Пневмония может развиться в любом возрасте, но чаще всего она возникает у детей раннего возраста, у которых чаще встречается и более тяжелое течение пневмонии. Ранняя диагностика и прогноз тяжести заболевания у детей являются актуальной проблемой на современном этапе. Было обнаружено, что в большинстве случаев комбинация традиционных биомаркеров, включая количество лейкоцитов, прокальцитонин, СРБ недостаточно эффективны в диагностике внебольничной пневмонии у детей. Актуальным является поиск новых маркеров, позволяющих в дополнение к клинической оценке существенно улучшить диагностику и ведение внебольничной пневмонии у детей и уменьшить неблагоприятные исходы, связанные с этим заболеванием. Такими маркерами могут стать цитокины, которые являются активными участниками патогенеза при внебольничной пневмонии. Целью данного исследования стало определение уровеня ряда цитокинов в сыворотке крови у детей с ВП и оценка изменения цитокинового профиля в зависимости от влияния факторов: возраст пациента и тяжесть заболевания. В исследовании были включены 117 детей в возрасте от 1 года до 18 лет с верифицированным диагнозом внебольничной пневмонии, подтвержденной рентгенологически. Группа сравнения сформирована из 28 здоровых детей, не имеющих на момент обследования внебольничной пневмонии, а также других признаков острой респираторной вирусной инфекции и не состоящих на диспансерном наблюдении по поводу какой-либо хронической патологии. Были определены уровни следующих цитокинов в сыворотке крови: IL-1β, IFNγ, IL-2, IL-4, IL-6, IL-10, TNFα, IFNλ2 (IL-28A), IFNλ3 (IL-28B), IL-8, MCP-1, IL-17AF, GM-CSF с помощью тест-систем, основанных на «сэндвич»-методе твердофазного ИФА с применением пероксидазы в качестве индикаторного фермента. В результате проведенного исследования было установлено, что содержание IL-6, IL-17AF, IL-1β, IFNγ, MCP-1, IFNλ2 (IL-28A), IFNλ3 (IL-28B), GM-CSF было значительно выше в группе детей с тяжелой внебольничной пневмонией. Уровень таких цитокинов, как IL-6, IFNλ2 (IL-28A), IFNλ3 (IL-28B), GM-CSF изменялся в зависимости от возраста пациентов, что может отражать степень активации иммунной системы у детей в различные возрастные периоды.</p></abstract><trans-abstract xml:lang="en"><p>Community-acquired pneumonia (CAP) is one of the most common acute infectious diseases. To date, the incidence of CAP among children was decreased significantly worldwide, mainly due to increasing use of effective preventive measures. Nevertheless, CAP remains a common cause of childhood morbidity and mortality. Pneumonia may develop at any age, but most often it occurs in young children, who are more likely to have a more severe course of pneumonia. Currently, early diagnosis and prognosis of the disease severity in children is an urgent issue. It was found that, in most cases, a panel of conventional biomarkers, including the number of leukocytes, procalcitonin, CRP is not sufficient for the diagnosis of pediatric CAP. There is a demand for new biological markers which, along with clinical evaluation, may significantly improve diagnostics and management of CAP in children, thus reducing the risk of adverse outcomes associated with this disease. Such markers could be found among the cytokines, which are active participants in the CAP pathogenesis. The aim of this study was to determine the level of several cytokines in blood serum of children with CAP and to assess changes in the cytokine profile depending on the patient’s age and severity of the disease. The study included 117 children aged 1 to 18 years with a diagnosis of CAP confirmed by X-ray examination. The comparison group included 28 healthy children who did not have CAP or other signs of acute respiratory viral infection at the time of examination, being free of any chronic pathology requiring outpatient observation. A number of cytokines were determined quantitatively in blood serum, i.e., IL-1β, IFNγ, IL-2, IL-4, IL-6, IL-10, TNFα, IFNλ2 (IL-28A), IFNλ3 (IL-28B), IL-8, MCP-1, IL-17AF, GM-CSF using test systems based on the “sandwich” method of solid-phase ELISA using peroxidase labeling. As a result, it was found that the content of IL-6, IL-17AF, IL-1β, IFNγ, MCP-1, IFNλ2 (IL-28A), IFNλ3 (IL-28B), GM-CSF was significantly higher in the group of children with severe community-acquired pneumonia. The levels of certain cytokines, e.g., IL-6, IFNλ2 (IL-28A), IFNλ3 (IL-28B), GM-CSF varied depending on the age of patients, thus, probably, reflecting the degree of immune system activation in the children of different age groups.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>внебольничная пневмония</kwd><kwd>тяжелая пневмония</kwd><kwd>дети</kwd><kwd>цитокины</kwd><kwd>интерфероны</kwd><kwd>маркеры пневмонии</kwd></kwd-group><kwd-group xml:lang="en"><kwd>community-acquired pneumonia</kwd><kwd>severe pneumonia</kwd><kwd>children</kwd><kwd>cytokines</kwd><kwd>interferons</kwd><kwd>pneumonia markers</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Геппе Н.А., Малахов А.Б., Дронов И.А., Хабибуллина Е.А. Внебольничная пневмония у детей: проблемы диагностики, лечения и профилактики // Доктор.Ру, 2015. № 13 (114). С. 20-27.</mixed-citation><mixed-citation xml:lang="en">Geppe N.A., Malakhov A.B., Dronov I.A., Khabibullina E.A. Community-acquired pneumonia in children: problems of diagnosis, treatment and prevention. Doktor.Ru = Doktor.Ru, 2015, no. 13 (114), pp. 20-27. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Зайцева О.В. Формирование иммунитета: актуальные вопросы педиатрии // Аллергология и иммунология в педиатрии, 2014. № 2 (37). С. 12-22.</mixed-citation><mixed-citation xml:lang="en">Zaitseva O.V. Formation of immunity: topical issues of pediatrics. Allergologiya i immunologiya v pediatrii = Allergology and Immunology in Pediatrics, 2014, no. 2 (37), pp. 12-22. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Пикуза О.И., Самороднова Е.А. Современные особенности внебольничных пневмоний у детей раннего возраста // Практическая медицина, 2013. № 6 (75). С. 35-41.</mixed-citation><mixed-citation xml:lang="en">Pikuza O.I., Samorodnova E.A. Modern features of community-acquired pneumonia in young children. Prakticheskaya meditsina = Practical Medicine, 2013, no. 6 (75), pp. 35-41. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Пневмония (внебольничная). Оригинал-макет, 2022. 82 с. [Электронный ресурс]. Режим доступа: https://cr.minzdrav.gov.ru/schema/714_1.</mixed-citation><mixed-citation xml:lang="en">Pneumonia (community-acquired). Original layout, 2022. 82 p. [Electronic resource]. Access mode: https://cr.minzdrav.gov.ru/schema/714_1.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Узунова А.Н. Пневмонии в детском возрасте. Челябинск: Челяб. гос. мед. акад., 2002. 215 с.</mixed-citation><mixed-citation xml:lang="en">Uzunova A.N. Pneumonia in childhood. Chelyabinsk: Chelyabinsk State Medical Academy, 2002. 215 p.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bacci M.R., Leme R.C., Zing N.P., Murad N., Adami F., Hinnig P.F., Feder D., Chagas A.C., Fonseca F.L. IL-6 and TNF-α serum levels are associated with early death in community-acquired pneumonia patients. Braz. J. Med. Biol. Res., 2015, Vol. 48, no. 5, pp. 427-432.</mixed-citation><mixed-citation xml:lang="en">Bacci M.R., Leme R.C., Zing N.P., Murad N., Adami F., Hinnig P.F., Feder D., Chagas A.C., Fonseca F.L. IL-6 and TNF-α serum levels are associated with early death in community-acquired pneumonia patients. Braz. J. Med. Biol. Res., 2015, Vol. 48, no. 5, pp. 427-432.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Banerjee R. CON: Procalcitonin does not have clinical utility in children with community-acquired pneumonia. JAC Antimicrob. Resist., 2021, Vol. 3, no. 4, dlab152. doi: 10.1093/jacamr/dlab152.</mixed-citation><mixed-citation xml:lang="en">Banerjee R. CON: Procalcitonin does not have clinical utility in children with community-acquired pneumonia. JAC Antimicrob. Resist., 2021, Vol. 3, no. 4, dlab152. doi: 10.1093/jacamr/dlab152.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bonaventura A., Vecchié A., Wang T.S., Lee E., Cremer P.C., Carey B., Rajendram P., Hudock K.M., Korbee L., van Tassell B.W., Dagna L., Abbate A. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. Front. Immunol., 2020, Vol. 11, 1625. doi: 10.3389/fimmu.2020.01625.</mixed-citation><mixed-citation xml:lang="en">Bonaventura A., Vecchié A., Wang T.S., Lee E., Cremer P.C., Carey B., Rajendram P., Hudock K.M., Korbee L., van Tassell B.W., Dagna L., Abbate A. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. Front. Immunol., 2020, Vol. 11, 1625. doi: 10.3389/fimmu.2020.01625.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">de Brito R.C., Lucena-Silva N., Torres L.C., Luna C.F., Correia J.B., da Silva G.A. The balance between the serum levels of IL-6 and IL-10 cytokines discriminates mild and severe acute pneumonia. BMC Pulm. Med., 2016, Vol. 16, no. 1, 170. doi: 10.1186/s12890-016-0324-z.</mixed-citation><mixed-citation xml:lang="en">de Brito R.C., Lucena-Silva N., Torres L.C., Luna C.F., Correia J.B., da Silva G.A. The balance between the serum levels of IL-6 and IL-10 cytokines discriminates mild and severe acute pneumonia. BMC Pulm. Med., 2016, Vol. 16, no. 1, 170. doi: 10.1186/s12890-016-0324-z.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandes C.D., Arriaga M.B., Costa M.C.M., Costa M.C.M., Costa M.H.M., Vinhaes C.L., SilveiraMattos P.S., Fukutani K.F., Andrade B.B. Host inflammatory biomarkers of disease severity in pediatric community-acquired pneumonia: a systematic review and meta-analysis. Open Forum Infect. Dis., 2019, Vol. 6, no. 12, ofz520. doi: 10.1093/ofid/ofz520.</mixed-citation><mixed-citation xml:lang="en">Fernandes C.D., Arriaga M.B., Costa M.C.M., Costa M.C.M., Costa M.H.M., Vinhaes C.L., SilveiraMattos P.S., Fukutani K.F., Andrade B.B. Host inflammatory biomarkers of disease severity in pediatric community-acquired pneumonia: a systematic review and meta-analysis. Open Forum Infect. Dis., 2019, Vol. 6, no. 12, ofz520. doi: 10.1093/ofid/ofz520.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Fukuda Y., Homma T., Inoue H., Onitsuka C., Ikeda H., Goto Y., Sato Y., Kimura T., Hirai K., Ohta S., Yamamoto M., Kusumoto S., Suzuki S., Tanaka A., Sagara H. Downregulation of type III interferons in patients with severe COVID-19. J. Med. Virol., 2021, Vol. 93, no. 7, pp. 4559-4563.</mixed-citation><mixed-citation xml:lang="en">Fukuda Y., Homma T., Inoue H., Onitsuka C., Ikeda H., Goto Y., Sato Y., Kimura T., Hirai K., Ohta S., Yamamoto M., Kusumoto S., Suzuki S., Tanaka A., Sagara H. Downregulation of type III interferons in patients with severe COVID-19. J. Med. Virol., 2021, Vol. 93, no. 7, pp. 4559-4563.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Galani I.E., Rovina N., Lampropoulou V., Triantafyllia V., Manioudaki M., Pavlos E., Koukaki E., Fragkou P.C., Panou V., Rapti V., Koltsida O., Mentis A., Koulouris N., Tsiodras S., Koutsoukou A., Andreakos E. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol., 2021, Vol. 22, no. 1, pp. 32-40.</mixed-citation><mixed-citation xml:lang="en">Galani I.E., Rovina N., Lampropoulou V., Triantafyllia V., Manioudaki M., Pavlos E., Koukaki E., Fragkou P.C., Panou V., Rapti V., Koltsida O., Mentis A., Koulouris N., Tsiodras S., Koutsoukou A., Andreakos E. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol., 2021, Vol. 22, no. 1, pp. 32-40.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hammer O., Harper D.A.T., Ryan P.D. PAST: Paleontological Statistics Software Package for Education and Data Analysis. Palaeontologia Electronica, 2001, Vol. 4, iss. 1, 9 p. Available at: https://palaeo-electronica.org/2001_1/past/issue1_01.htm.</mixed-citation><mixed-citation xml:lang="en">Hammer O., Harper D.A.T., Ryan P.D. PAST: Paleontological Statistics Software Package for Education and Data Analysis. Palaeontologia Electronica, 2001, Vol. 4, iss. 1, 9 p. Available at: https://palaeo-electronica.org/2001_1/past/issue1_01.htm.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Haugen J., Chandyo R.K., Brokstad K.A., Mathisen M., Ulak M., Basnet S., Valentiner-Branth P., Strand T.A. Cytokine concentrations in plasma from children with severe and non-severe community acquired pneumonia. PLoS One, 2015, Vol. 10, no. 9, e0138978. doi: 10.1371/journal.pone.0138978.</mixed-citation><mixed-citation xml:lang="en">Haugen J., Chandyo R.K., Brokstad K.A., Mathisen M., Ulak M., Basnet S., Valentiner-Branth P., Strand T.A. Cytokine concentrations in plasma from children with severe and non-severe community acquired pneumonia. PLoS One, 2015, Vol. 10, no. 9, e0138978. doi: 10.1371/journal.pone.0138978.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jin H.L., Zhan L., Mei S.F., Shao Z.Y. Serum cytokines and FeNO in school-aged children with mycoplasma pneumoniae pneumonia. Med. Sci. Monit., 2020, Vol. 26, e923449. doi: 10.12659/MSM.923449.</mixed-citation><mixed-citation xml:lang="en">Jin H.L., Zhan L., Mei S.F., Shao Z.Y. Serum cytokines and FeNO in school-aged children with mycoplasma pneumoniae pneumonia. Med. Sci. Monit., 2020, Vol. 26, e923449. doi: 10.12659/MSM.923449.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Khaedir Y., Kartika R. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19. J. Interferon Cytokine Res., 2021, Vol. 41, no. 2, pp. 37-43.</mixed-citation><mixed-citation xml:lang="en">Khaedir Y., Kartika R. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19. J. Interferon Cytokine Res., 2021, Vol. 41, no. 2, pp. 37-43.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kleiner G., Marcuzzi A., Zanin V., Monasta L., Zauli G. Cytokine levels in the serum of healthy subjects. Mediators Inflamm., 2013, Vol. 2013, 434010. doi: 10.1155/2013/434010.</mixed-citation><mixed-citation xml:lang="en">Kleiner G., Marcuzzi A., Zanin V., Monasta L., Zauli G. Cytokine levels in the serum of healthy subjects. Mediators Inflamm., 2013, Vol. 2013, 434010. doi: 10.1155/2013/434010.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">le Roux D.M., Zar H.J. Community-acquired pneumonia in children – a changing spectrum of disease. Pediatr. Radiol., 2017, Vol. 47, no. 11, pp. 1392-1398.</mixed-citation><mixed-citation xml:lang="en">le Roux D.M., Zar H.J. Community-acquired pneumonia in children – a changing spectrum of disease. Pediatr. Radiol., 2017, Vol. 47, no. 11, pp. 1392-1398.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J.E., Kim J.W., Han B.G., Shin S.Y. Impact of whole-blood processing conditions on plasma and serum concentrations of cytokines. Biopreserv. Biobank., 2016, Vol. 14, no. 1, pp. 51-55.</mixed-citation><mixed-citation xml:lang="en">Lee J.E., Kim J.W., Han B.G., Shin S.Y. Impact of whole-blood processing conditions on plasma and serum concentrations of cytokines. Biopreserv. Biobank., 2016, Vol. 14, no. 1, pp. 51-55.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Liu C., Chu D., Kalantar-Zadeh K., George J., Young H.A., Liu G. Cytokines: from clinical significance to quantification. Adv. Sci. (Weinh), 2021, Vol. 8, no. 15, e2004433. doi: 10.1002/advs.202004433.</mixed-citation><mixed-citation xml:lang="en">Liu C., Chu D., Kalantar-Zadeh K., George J., Young H.A., Liu G. Cytokines: from clinical significance to quantification. Adv. Sci. (Weinh), 2021, Vol. 8, no. 15, e2004433. doi: 10.1002/advs.202004433.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Liu M., Lu B., Fan H., Guo X., Du S., Yang D., Xu Y., Li Y., Che D., Liu Y., Gu X., Ding T., Wang P., Luo H.B., Lu G. Heightened local Th17 cell inflammation is associated with severe community-acquired pneumonia in children under the age of 1 year. Mediators Inflamm. , 2021, Vol. 2021, 9955168. doi: 10.1155/2021/9955168.</mixed-citation><mixed-citation xml:lang="en">Liu M., Lu B., Fan H., Guo X., Du S., Yang D., Xu Y., Li Y., Che D., Liu Y., Gu X., Ding T., Wang P., Luo H.B., Lu G. Heightened local Th17 cell inflammation is associated with severe community-acquired pneumonia in children under the age of 1 year. Mediators Inflamm. , 2021, Vol. 2021, 9955168. doi: 10.1155/2021/9955168.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Potere N., Batticciotto A., Vecchié A., Porreca E., Cappelli A., Abbate A., Dentali F., Bonaventura A. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev. Clin. Immunol., 2021, Vol. 17, no. 6, pp. 601-618.</mixed-citation><mixed-citation xml:lang="en">Potere N., Batticciotto A., Vecchié A., Porreca E., Cappelli A., Abbate A., Dentali F., Bonaventura A. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev. Clin. Immunol., 2021, Vol. 17, no. 6, pp. 601-618.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Principi N., Esposito S. Biomarkers in pediatric community-acquired pneumonia. Int. J. Mol. Sci., 2017, Vol. 18, no. 2, 447. doi: 10.3390/ijms18020447.</mixed-citation><mixed-citation xml:lang="en">Principi N., Esposito S. Biomarkers in pediatric community-acquired pneumonia. Int. J. Mol. Sci., 2017, Vol. 18, no. 2, 447. doi: 10.3390/ijms18020447.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ritchie N.D., Ritchie R., Bayes H.K., Mitchell T.J., Evans T.J. IL-17 can be protective or deleterious in murine pneumococcal pneumonia. PLoS Pathog., 2018, Vol. 14, no. 5, e1007099. doi: 10.1371/journal.ppat.1007099.</mixed-citation><mixed-citation xml:lang="en">Ritchie N.D., Ritchie R., Bayes H.K., Mitchell T.J., Evans T.J. IL-17 can be protective or deleterious in murine pneumococcal pneumonia. PLoS Pathog., 2018, Vol. 14, no. 5, e1007099. doi: 10.1371/journal.ppat.1007099.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol., 2018, Vol. 10, no. 2, a028415. doi: 10.1101/cshperspect.a028415.</mixed-citation><mixed-citation xml:lang="en">Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol., 2018, Vol. 10, no. 2, a028415. doi: 10.1101/cshperspect.a028415.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Saghafian-Hedengren S., Mathew J.L., Hagel E., Singhi S., Ray P., Ygberg S., Nilsson A. Assessment of cytokine and chemokine signatures as potential biomarkers of childhood community-acquired pneumonia severity: a nested cohort study in india. Pediatr. Infect. Dis. J., 2017, Vol. 36, no. 1, pp. 102-108.</mixed-citation><mixed-citation xml:lang="en">Saghafian-Hedengren S., Mathew J.L., Hagel E., Singhi S., Ray P., Ygberg S., Nilsson A. Assessment of cytokine and chemokine signatures as potential biomarkers of childhood community-acquired pneumonia severity: a nested cohort study in india. Pediatr. Infect. Dis. J., 2017, Vol. 36, no. 1, pp. 102-108.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Sokal R.R., Rohlf F.J. Biometry, the principles and practice of statistics in biological research, 3 rd ed.; W.H. Freeman and Co.: New York, NY, USA, 1997.</mixed-citation><mixed-citation xml:lang="en">Sokal R.R., Rohlf F.J. Biometry, the principles and practice of statistics in biological research, 3 rd ed.; W.H. Freeman and Co.: New York, NY, USA, 1997.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Stanifer M.L., Guo C., Doldan P., Boulant S. Importance of Type I and III interferons at respiratory and intestinal barrier surfaces. Front. Immunol., 2020, Vol. 11, 608645. doi: 10.3389/fimmu.2020.608645.</mixed-citation><mixed-citation xml:lang="en">Stanifer M.L., Guo C., Doldan P., Boulant S. Importance of Type I and III interferons at respiratory and intestinal barrier surfaces. Front. Immunol., 2020, Vol. 11, 608645. doi: 10.3389/fimmu.2020.608645.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson R., Cohen J.M., Jose R.J., de Vogel C., Baxendale H., Brown J.S. Protection against Streptococcus pneumoniae lung infection after nasopharyngeal colonization requires both humoral and cellular immune responses. Mucosal Immunol., 2015, Vol. 8, no. 3, pp. 627-639.</mixed-citation><mixed-citation xml:lang="en">Wilson R., Cohen J.M., Jose R.J., de Vogel C., Baxendale H., Brown J.S. Protection against Streptococcus pneumoniae lung infection after nasopharyngeal colonization requires both humoral and cellular immune responses. Mucosal Immunol., 2015, Vol. 8, no. 3, pp. 627-639.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Revised WHO Classification and Treatment of Childhood Pneumonia at Health Facilities: Evidence Summaries. Geneva: World Health Organization; 2014. Available at: https://www.ncbi.nlm.nih.gov/books/NBK264162/.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Revised WHO Classification and Treatment of Childhood Pneumonia at Health Facilities: Evidence Summaries. Geneva: World Health Organization; 2014. Available at: https://www.ncbi.nlm.nih.gov/books/NBK264162/.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Ye L., Schnepf D., Staeheli P. Interferon-λ orchestrates innate and adaptive mucosal immune responses. Nat. Rev. Immunol., 2019, Vol. 19, no. 10, pp. 614-625.</mixed-citation><mixed-citation xml:lang="en">Ye L., Schnepf D., Staeheli P. Interferon-λ orchestrates innate and adaptive mucosal immune responses. Nat. Rev. Immunol., 2019, Vol. 19, no. 10, pp. 614-625.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Yong K.K., Chang J.H., Chien M.H., Tsao S.M., Yu M.C., Bai K.J., Tsao T.C., Yang S.F. Plasma Monocyte chemoattractant protein-1 level as a predictor of the severity of community-Acquired Pneumonia. Int. J. Mol. Sci., 2016, Vol. 17, no. 2, 179. doi: 10.3390/ijms17020179.</mixed-citation><mixed-citation xml:lang="en">Yong K.K., Chang J.H., Chien M.H., Tsao S.M., Yu M.C., Bai K.J., Tsao T.C., Yang S.F. Plasma Monocyte chemoattractant protein-1 level as a predictor of the severity of community-Acquired Pneumonia. Int. J. Mol. Sci., 2016, Vol. 17, no. 2, 179. doi: 10.3390/ijms17020179.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshioka K. KyPlot – A User-oriented Tool for Statistical Data Analysis and Visualization. CompStat, 2002, Vol. 17, iss. 3, 425-437.</mixed-citation><mixed-citation xml:lang="en">Yoshioka K. KyPlot – A User-oriented Tool for Statistical Data Analysis and Visualization. CompStat, 2002, Vol. 17, iss. 3, 425-437.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
